Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,575 stopped studies mapped to Malignant Breast Neoplasm and descendants · 90% state a reason
Over the 1,575 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05990478 | A Study of Contrast-Enhanced Mammography (CEM) Scans in People With Breast Cancer | — | withdrawn | Aug 14, 2023 | Memorial Sloan Kettering Cancer Center | Challenges to participant accrual | Enrollment / accrual |
| NCT05744557 | Vapocoolant Analgesia for Breast Lymphoscintigraphy | N/A | terminated | Feb 27, 2023 | M.D. Anderson Cancer Center | \<75% accrued participants | Enrollment / accrual |
| NCT03742349 | Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple… | Phase 1 | terminated | Nov 15, 2018 | Novartis Pharmaceuticals | This was a sponsor decision and was not a consequence of any safety concern | Safety / toxicity |
| NCT04252859 | [18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma | Phase 2 | terminated | Feb 5, 2020 | University of Utah | PI is leaving the institution. | Other (stated, no rule matched) |
| NCT06145399 | A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer | Early Phase 1 | withdrawn | Nov 24, 2023 | Memorial Sloan Kettering Cancer Center | No accruals | Enrollment / accrual |
| NCT06978478 | An Imaging Study in ER Negative Breast Cancer by Targeting αvβ6(IMETAB6) | N/A | withdrawn | May 18, 2025 | Queen Mary University of London | EDGE Suspended 27/09/2022 | Other (stated, no rule matched) |
| NCT00195091 | Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer | Phase 2 | terminated | Sep 19, 2005 | Memorial Sloan Kettering Cancer Center | PI left MSKCC | Investigator |
| NCT01938833 | Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer | Phase 1 / Phase 2 | terminated | Sep 10, 2013 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Closed by Sponsor | Other (stated, no rule matched) |
| NCT04973930 | Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and…(IPT) | Phase 3 | suspended | Jul 22, 2021 | New York State Psychiatric Institute | NYSPI paused human subjects research (HSR) 6/23. The US Dept. of Health and Human Services Office… | Enrollment / accrual |
| NCT06231693 | Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast… | — | terminated | Jan 30, 2024 | AstraZeneca | The study was stopped due to a realignment of strategic priorities | Sponsor / business decision |
| NCT03596073 | Topical Calcipotriene Treatment for Breast Cancer Immunoprevention | Phase 1 | terminated | Jul 23, 2018 | Massachusetts General Hospital | Interim analysis did not show the required cytokine induction by topical calcipotriene to justify… | Efficacy / futility |
| NCT02810873 | Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast… | N/A | terminated | Jun 23, 2016 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Study terminated by PI | Other (stated, no rule matched) |
| NCT01349088 | Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally… | Phase 1 / Phase 2 | withdrawn | May 6, 2011 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | not stated | Not stated |
| NCT03054025 | Smart Phone Application in Increasing Physical Activity in Breast Cancer Survivors | N/A | terminated | Feb 15, 2017 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | funding discontinued | Funding |
| NCT04418219 | Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent,… | Phase 1 / Phase 2 | withdrawn | Jun 5, 2020 | Thomas Jefferson University | Funding Discontinued | Funding |
| NCT04875806 | A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid… | Phase 1 / Phase 2 | terminated | May 6, 2021 | NextCure, Inc. | Due to the limited activity in Phase 1, NextCure decided to discontinue development of the… | Other (stated, no rule matched) |
| NCT06938711 | A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With… | Phase 1 / Phase 2 | withdrawn | Apr 22, 2025 | Context Therapeutics Inc. | Change in corporate strategy. | Sponsor / business decision |
| NCT04533373 | Sensory Restoration After DIEP Flap Neurotization | N/A | terminated | Aug 31, 2020 | Johns Hopkins University | IRB expired | Other (stated, no rule matched) |
| NCT04965688 | Biology Guided Therapy for Breast Cancer for ER Positive(SPOCK) | Phase 2 | terminated | Jul 16, 2021 | Inova Health Care Services | Lack of enrollment to meet the primary and secondary study goals | Enrollment / accrual |
| NCT05940844 | Study of OB-002 in Patients With Refractory Metastatic Cancer | Phase 1 | withdrawn | Jul 11, 2023 | Orion Biotechnology Polska Sp. z o.o. | study terminated due to changes in the drug development plan | Other (stated, no rule matched) |
| NCT05867667 | Cardiac Rehabilitation to Improve Breast Cancer Outcomes(CRIBCO) | N/A | terminated | May 22, 2023 | University of Michigan Rogel Cancer Center | Insufficient Budget | Funding |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid… | Phase 2 | terminated | May 12, 2020 | Elevation Oncology | Business decision | Sponsor / business decision |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab… | Phase 1 / Phase 2 | terminated | Feb 4, 2019 | Kymab Limited | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT04339517 | Postoperative Identification of Tumor Cells At the Lumpectomy Site of Patients with Early… | N/A | suspended | Apr 9, 2020 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Low accrual | Enrollment / accrual |
| NCT05336721 | A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC | Phase 2 | terminated | Apr 20, 2022 | Chipscreen Biosciences, Ltd. | During the enrollment period of this project, due to the increasing proportion of patients… | Enrollment / accrual |
| NCT04889495 | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in… | — | withdrawn | May 17, 2021 | Pfizer | The study was withdrawn due to global supply chain issue. Zirabev was not launching in Korea. | Drug supply |
| NCT01315106 | High Resolution 3D Diffusion-weighted Breast MRI | — | terminated | Mar 15, 2011 | Stanford University | Business Decision | Sponsor / business decision |
| NCT06257758 | A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors | Phase 1 / Phase 2 | terminated | Feb 14, 2024 | Valerio Therapeutics | Business decision | Sponsor / business decision |
| NCT05576077 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors(STARLING) | Phase 1 | terminated | Oct 12, 2022 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT03175666 | QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy… | Phase 1 / Phase 2 | withdrawn | Jun 5, 2017 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT03554109 | QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine(TNBC) | Phase 2 | withdrawn | Jun 12, 2018 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT05554211 | Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage | Phase 2 | withdrawn | Sep 26, 2022 | Northwestern University | Medical student graduated and stopped project | Other (stated, no rule matched) |
| NCT03936933 | Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in… | Phase 3 | terminated | May 3, 2019 | Eurofarma Laboratorios S.A. | Low recruitment rate and number of subjects is less than required after 3 years. | Enrollment / accrual |
| NCT04142476 | Evaluation of the Impact of a Pharmaceutical Interview on the Adherence to Hormonotherapy…(HORMONOVILLE) | N/A | terminated | Oct 29, 2019 | Centre Georges Francois Leclerc | insufficient recruitment | Enrollment / accrual |
| NCT03941639 | Using Imaging Data and Genomic Data to Predict Metastasis of Breast Cancer After Treatment | — | terminated | May 8, 2019 | Chinese University of Hong Kong | lack a funding and withdrawal of collaborator | Funding |
| NCT05080842 | A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer | Phase 1 | terminated | Oct 18, 2021 | Accutar Biotechnology Inc | Voluntarily terminate the study since the sponsor's development strategy was adjusted. | Sponsor / business decision |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT06390241 | Avidination for RadionuclideTHerapy in Nonpalpable Breast Cancer(ARTHE) | Phase 1 | terminated | Apr 30, 2024 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Target enrolment was not met. The trial is terminated because the radiopharmaceutical is not… | Enrollment / accrual |
| NCT04151368 | Surgical and Patient Reported Outcomes of Robotic Nipple-Sparing Mastectomy(RNSM) | N/A | suspended | Nov 5, 2019 | University Health Network, Toronto | Recruitment has been temporarily suspended since the start of the pandemic due to the need for… | COVID-19 / pandemic |
| NCT05825768 | Preoperative Magnetic Resonance Imaging to Obtain Adequate Resection Margins in Breast…(PRIMAR) | N/A | terminated | Apr 24, 2023 | Aarhus University Hospital | Difficulties recruiting the patients at one of the sites. | Enrollment / accrual |
| NCT05113966 | Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast… | Phase 2 | terminated | Nov 9, 2021 | G1 Therapeutics, Inc. | The Sponsor decided to close enrollment to the study on Feb 14, 2023, in order to reallocate… | Enrollment / accrual |
| NCT05539365 | Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or… | Phase 2 | withdrawn | Sep 14, 2022 | Roswell Park Cancer Institute | Study never activated. | Other (stated, no rule matched) |
| NCT06341647 | Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 | Phase 1 | withdrawn | Apr 2, 2024 | GC Cell Corporation | Determined that enrollment would be limited due to the change in care setting. | Enrollment / accrual |
| NCT03779867 | Acute Exercise Intervention in Breast Cancer Survivors(ACE) | N/A | terminated | Dec 19, 2018 | Fred Hutchinson Cancer Center | Study closed per SRC low accrual policy. | Enrollment / accrual |
| NCT03609021 | Evaluation of Mammographic Breast Density in Participants with Hormone Receptor-Negative… | — | terminated | Aug 1, 2018 | Alliance for Clinical Trials in Oncology | A211601 closed prematurely due to slow accrual. | Enrollment / accrual |
| NCT04440982 | Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients | Phase 2 | terminated | Jun 22, 2020 | Lumicell, Inc. | Required resources unavailable. | Other (stated, no rule matched) |
| NCT03092635 | AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy | Phase 1 | terminated | Mar 28, 2017 | Medical University of South Carolina | Original principal investigator departed institution and concluded the study upon departure. | Investigator |
| NCT04256941 | Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive… | Phase 2 | terminated | Feb 5, 2020 | M.D. Anderson Cancer Center | Despite modifications, accrual was poor and the closed | Enrollment / accrual |
| NCT01897441 | Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC… | N/A | terminated | Jul 12, 2013 | Albert Einstein College of Medicine | Interventional component of study terminated prior to full enrollment | Enrollment / accrual |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Phase 1 / Phase 2 | terminated | Aug 15, 2022 | Aminex Therapeutics, Inc. | Required re-formulation of DFMO from IV to capsule to maintain safety | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 21, 2025source: clinicaltrials